Ergothioneine occurs in relatively few organisms, notably Actinobacteria, Cyanobacteria, and certain fungi. Since humans can’t produce it, it has to be exclusively acquired through the diet. Ongoing in vivo studies proved promising positive effects of the compound on human wellbeing. Since natural ergothioneine levels are extremely low, and it has to be elaborately isolated, alternative production methods are highly desired. For example, S. cerevisiae has been engineered for high-level production of ergothioneine.
acib’s concept is to use the ‘biotech’ yeast Pichia pastoris (syn. Komagataella phaffii), which is especially known for its growth to extremely high cell densities. This more than often proved it superior to S. cerevisiae in many industrial processes. Based on novel strain engineering techniques, and benefiting from previous studies, production levels of ergothioneine in genetically manipulated P. pastoris strains are expected to clearly exceed productivities of 2.4 g/L in 160 h currently obtained using S. cerevisiae.
Experts:Dr. Anita Emmerstorfer-Augustin
Investments, Joint Research Projects, Contract Research
Development status:Technology Readiness Level 2 (Technology concept formulated)
IPR:Can be generated for our industrial partners / investors
Keywords:Rare amino acids, Food supplement, Antioxidant, Health effects, Pharma Industry, Nutraceutical, Longevity
Picture credits: Pixabay